Exagen Inc (XGN) reports a robust financial performance with significant improvements in revenue, gross margin, and adjusted EBITDA in the first quarter of 2024.
Exagen ( NASDAQ:XGN ) First Quarter 2024 Results Key Financial Results Revenue: US$14.4m (up 28% from 1Q 2023). Net...
Exagen (XGN) delivered earnings and revenue surprises of 52.50% and 9.21%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?